PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.59%
Both companies show declining cash positions (-7.59% vs AGEN's -28.40%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Below half of AGEN's -28.40%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of AGEN's 1.85%. David Dodd sees a leaner approach to short-term items.
-8.57%
0.75-0.9x AGEN's -10.46%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
-5.56%
1.25-1.5x AGEN's -3.93%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.97%
Higher Long-Term Investments Growth compared to AGEN's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
1.25-1.5x AGEN's -4.01%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
1.25-1.5x AGEN's -6.43%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
-2.42%
Less than half of AGEN's 50.34%. David Dodd sees a more disciplined AP approach or lower volume.
3.64%
Less than half of AGEN's -62.27%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-101.55%
Similar yoy growth to AGEN's -99.64%. Walter Schloss notes parallel approach to deferred revenue.
-3.64%
Less than half of AGEN's 41.69%. David Dodd sees fewer expansions in other current obligations.
-2.05%
Less than half of AGEN's 29.01%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.51%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to AGEN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.32%
Less than half of AGEN's -18.23%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-0.65%
Less than half of AGEN's 2.56%. David Dodd sees far fewer liability expansions relative to competitor.
3.70%
Similar yoy changes to AGEN's 3.41%. Walter Schloss sees parallel capital-raising strategies.
-2.84%
1.25-1.5x AGEN's -2.42%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.53%
0.5-0.75x AGEN's -24.18%. Martin Whitman is wary of lagging equity growth vs. competitor.
-8.43%
1.25-1.5x AGEN's -6.43%. Bruce Berkowitz checks if expansions are well-justified by ROI.
0.97%
Higher Total Investments Growth compared to AGEN's zero value, indicating better performance.
-4.43%
Less than half of AGEN's 293.44%. David Dodd sees less overall debt expansion vs. competitor.
7.68%
Less than half of AGEN's 1686.16%. David Dodd sees better deleveraging or stronger cash buildup than competitor.